Stockreport

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension [Yahoo!...

Mineralys Therapeutics, Inc.  (MLYS) 
PDF blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value – Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction [Read more]